Iorns et al. [27] have shown that CDK10 gene knockdown reproducibly caused resistance to tamoxifen treatment, and these authors also showed that CDK10 could make tamoxifen more effective in treating breast cancer through C-RAF/MAPK kinase pathway activity [27]. Here, RAF1 is linked to breast carcinoma.